MOUNTAIN VIEW, Calif., Sept. 20 /PRNewswire/ -- Cardiva Medical, Inc., a privately held medical device company, announced today that Augustine Lien, Chairman and CEO, will present at the UBS 2007 Global Life Science Conference on Tuesday, September 25th in New York City. Notably, the company will be positioned to share information on its newest device, the Boomerang Catalyst II System, which recently received a 510(K) US market clearance. This new product builds on the success of its predecessor, the Boomerang Catalyst System TM, which launched in July 2007 with fast acceptance from cardiac centers across the U.S. given its unique product profile. Specifically, both the Boomerang Catalyst System and Boomerang Catalyst II System are the first vascular closure devices to achieve final hemostasis in the catheterization lab without leaving any foreign materials behind in the vessel, thereby eliminating a major cause of device failures, complications and re-access challenges.
Approved for both diagnostic and interventional procedures, Cardiva
first introduced the original Boomerang Wire System in May 2005. While
continuing to evolve its portfolio to meet the needs of its customers,
Cardiva successfully enhanced the Boomerang Wire System in early 2007 by
adding a proprietary hemostatic material to the spring-loaded section of
the Boomerang Wire which accelerates coagulation adjacent to the puncture
site. Cardiva launched this newly approved device in July as "Boomerang
Catalyst System." The company has since enhanced the Boomerang Catalyst
System to further improve the clinical performance of the Boomerang
technology by adding an additional pro-coagulant to the proprietary
hemostatic material of the Catalyst System. This new product will be
released to the market under a trade name of "Boomerang Catalyst II System"
in the fourth quarter of this year. To date, the portfolio of Boomerang
devices has been used in more than 80,000 percutaneous catheterization
|SOURCE Cardiva Medical, Inc.|
Copyright©2007 PR Newswire.
All rights reserved